exposure to isotretinoin experienced AE related to surgery. Of the 2 exposed patients with an AE, 1 was taking isotretinoin at the time of surgery and continued postoperatively until course completion and 1 had completed the course 2 months prior (Table I) .
Oral retinoids have been associated with suppression of collagenase, potentially causing excessive collagen accumulation and keloid formation, and possible atrophy of the pilosebaceous unit, where re-epithelialization for wound healing originates. [1] [2] [3] [4] [5] A review of the literature showed that the AEs associated with surgical procedures performed on persons with isotretinoin exposure included nasal tip deformities (2 patients), slow wound healing (1 of 3 patients undergoing otolaryngologic surgery), slow healing (1 patient undergoing pilonidal cyst excision), and dry socket (3 of 25 patients with wisdom teeth extractions) ( Table I) . 5 The largest published study of 183 patients who underwent 504 surgical interventions while on isotretinoin reported 2 AE (0.4%) of keloid formation: 1 after radiofrequency ablation and the other after glycolic acid peel. 4 These complications could have been attributed to the aforementioned procedures; thus a causative effect of isotretinoin exposure was not clearly demonstrated.
Our study evaluated surgical outcomes in an otherwise healthy and similar population of patients exposed and unexposed to isotretinoin who had a large number and variety of incisional procedures. The large sample of patients with acne severe enough to be considered for isotretinoin therapy allowed us to effectively control for acne severity, a factor which could also contribute to scar formation or alteration in wound healing.
In summary, from medical record review, wound healing did not appear to be affected, and abnormal scarring did not appear to be evident in patients undergoing isotretinoin therapy as compared with those not exposed to the medication in the perioperative period. Because this study is limited by an overall low level of AE and its retrospective nature, the findings challenge the current practice of waiting 6-12 months to have elective surgery after isotretinoin exposure. Taking into consideration the small pool of case-based literature from which the recommendation to discontinue isotretinoin developed, a re-evaluation of this practice should be considered. Methotrexate treatment in patients with a history of cutaneous melanoma and the risk of a consecutive primary melanoma: A national retrospective registry-based cohort study
To the Editor: Methotrexate (MTX) has been used as an immunosuppressive and antiinflammatory drug since the middle of the 20th century. Because of its early introduction and widespread use, MTX has escaped the rigorous clinical trials that constitute the fundament for the introduction of novel pharmaceutical drugs being developed today. 1 In a previous publication, we found a small but significant increase in risk for cutaneous malignant melanoma (CMM) in patients with MTX exposure without a previous melanoma. 2 However, the risk increase observed was considerably lower than earlier observations. 3 In a clinical setting, there is no consensus on whether MTX should be discontinued if a patient develops a CMM during treatment. Moreover, it is unknown whether a history of CMM and ongoing MTX treatment enhances the risk for a new CMM. To evaluate whether MTX treatment after a diagnosis of CMM increases the risk for a consecutive primary melanoma, a national retrospective registry-based cohort study was performed. Data were requested from the Swedish Prescribed Drug Register 4 for all patients in Sweden [18 years of age who were dispensed MTX between 2005 and 2014. For each MTX-exposed patient, 5 age-and sex-matched MTX-unexposed patients that had been dispensed any other random pharmaceutical drug were randomly selected. The generated data were matched to the Swedish Cancer Registry, 5 and all history of CMM, including melanoma in situ, was obtained from the start of the registry in 1958 until 2014. This study was approved by the Institutional Review Board of Gothenburg University.
Among 101,966 MTX-exposed and 509,279 MTXunexposed patients, 1216 and 6696, respectively, had a history of CMM and were included in the analysis (Table I) .
In the MTX-exposed group, 105 of 1216 patients (8.6% [95% confidence interval {CI}], 7.1%-10.4%) developed a consecutive primary CMM. In the MTX-unexposed group, the corresponding number was 553 of 6695 patients (8.3% [95% CI, 7.6%-8.9%]; P ¼ .65, Fisher's exact test). A Cox proportional hazards regression, controlling for age group, sex, and time interval from the first CMM found no significantly increased risk for a consecutive primary CMM in the MTX-exposed group compared to the MTX-unexposed group (hazard ratio ¼ 1.0 [95% CI, 0.8-1.2]; P ¼ .98). The KaplaneMeier estimates for the 5-year risk of a consecutive primary CMM was 5.7% (95% CI, 4.3%-7.1%) in the MTX-exposed group and 6.1% (95% CI, 5.5%-6.7%) in the MTX-unexposed group (Fig 1) .
Moreover, there was no significant difference in incidence between the MTX-exposed and MTX-unexposed groups (data not shown).
Limitations of this study include no access to data regarding MTX prescription before 2005, the retrospective design, not accounting for risk factors, such as skin type, history of sunburn, history of sun exposure, psoralen plus ultraviolet A light phototherapy treatments, and family history of CMM. In addition, the concomitant use of other drugs potentially influencing the risk for CMM was not obtained. The MTX-exposed group was constituted by patients with a history of a first CMM and MTX exposure after the diagnosis of the first CMM. The MTX-unexposed group consisted of patients with a history of a first CMM without MTX exposure. CMM, Cutaneous malignant melanoma; MTX, methotrexate. *Observation period is ended by whatever comes first: the date of a consecutive primary CMM, death, or the end of the study period.
In this nationwide retrospective cohort study, our results suggest that a history of CMM does not impose a higher risk for development of a consecutive primary CMM in patients treated with MTX compared to patients without MTX exposure after the diagnosis of CMM.
A prospective evaluation of the candle wax sign: A visual clue to diagnose aggressive basal cell carcinoma To the Editor: There is a presentation of basal cell carcinoma (BCC) that appears as a subtle hypopigmented macule or patch, rarely with a slight xanthomatous hue and mild induration. The smooth surface is reminiscent of a drop of candle wax that fell and hardened as a delicate, gossamer film. Though the features of aggressive BCCs are well described in the literature, typically presenting as vaguely margined, white, indurated, scar-like plaques, [1] [2] [3] this subtype of aggressive BCC is not raised, presenting more as a restrained investment of the epidermal surface. The color, unlike the distinct white appearance of a morpheaform BCC, will largely blend with the immediately surrounding skin. Being flat and smooth, the malignancy typically does not generate an appreciable tactile change. Figs 1 and 2 show 2 representative examples.
To facilitate recognition and earlier diagnosis, this article attaches 2 descriptive appellations to this diagnostically challenging subtype of aggressive BCC; the candle wax sign to the visual finding and candle wax BCC (CWBCC) to the clinical entity.
For 1 year, CWBCCs were documented in a Mohs micrographic surgery practice.
Criteria for inclusion included the above clinical description and biopsy specimen results read by an outside dermatopathology laboratory confirming the diagnosis of BCC. The prospective study generated 1027 nonmelanoma skin cancers (NMSCs), including 748 BCCs. Twenty-one cases met the criteria. Each of these patients had been receiving at least annual examinations by a primary care provider.
Histologically, the CWBCCs were composed of infiltrative (8), micronodular (6), sclerosing (2) , and desmoplastic (1) subtypes. Four cases were a mix of subtypes. All cases were treated by the same surgeon KaplaneMeier estimates for the proportion of patients that did not develop a second cutaneous melanoma (CMM) in the methotrexate (MTX)-exposed and MTX-unexposed groups. The number of patients at risk in the respective groups is specified at 0, 15, 30, and 45 years after the first reported CMM. The data include both in situ and invasive melanomas. The observation period constituted the time from the first CMM diagnosis to whichever came first: the end of the study period (December 31, 2014), death, or the diagnosis of a consecutive primary CMM. Local recurrence of a melanoma was not included as a consecutive primary CMM.
